Dr. Leonard Marks holds the position of Dekernion Endowed Chair in the Urology Department at the David Geffen School of Medicine at UCLA. His pre-medical education was at Tulane University; Medical School (M.D.) and Graduate School (M.A.) were at the University of Texas; and his urology residency was at UCLA under the primary tutelage of Prof. Joseph Kaufman.
Following residency, he entered the practice of urology in Los Angeles, where he also founded the Urological Sciences Research Foundation, a California non-profit organization. After a lengthy career in practice, Dr. Marks returned to the fulltime faculty of the urology department at UCLA in 2009.
At UCLA, Dr. Marks has focused on contemporary management of prostate cancer. He initiated MRI-guided biopsy at that institution in 2009, one of the earliest of such programs; the program, which started at that time, has become one of the largest in the world. Funding for the program has come from three separate grants from the National Cancer Institute and from private philanthropy. Nearly 100 publications deriving from that work have appeared in major medical journals, and numerous trainees have taken the concepts to various other institutions. Among discoveries emanating from the UCLA program are the superiority of MRI in finding prostate cancer; the value of combining systematic and targeted prostate biopsies; the advantage of using MRI-guided biopsy to determine eligibility for active surveillance; and the role of MRI/US fusion for guiding focal laser ablation.
The multi-disciplinary group assembled at UCLA (urology, radiology, pathology, biomedical engineering) has served as a model for study of image-guided diagnosis and treatment. The work which led to FDA-approval of HIFU (and publication of the data) was spearheaded by Dr. Marks at UCLA. A UCLA-backed startup, co-founded by Dr. Marks and funded in part by NCI, will soon place into trials a proprietary device for office-based focal laser ablation of prostate cancer.
Following residency, he entered the practice of urology in Los Angeles, where he also founded the Urological Sciences Research Foundation, a California non-profit organization. After a lengthy career in practice, Dr. Marks returned to the fulltime faculty of the urology department at UCLA in 2009.
At UCLA, Dr. Marks has focused on contemporary management of prostate cancer. He initiated MRI-guided biopsy at that institution in 2009, one of the earliest of such programs; the program, which started at that time, has become one of the largest in the world. Funding for the program has come from three separate grants from the National Cancer Institute and from private philanthropy. Nearly 100 publications deriving from that work have appeared in major medical journals, and numerous trainees have taken the concepts to various other institutions. Among discoveries emanating from the UCLA program are the superiority of MRI in finding prostate cancer; the value of combining systematic and targeted prostate biopsies; the advantage of using MRI-guided biopsy to determine eligibility for active surveillance; and the role of MRI/US fusion for guiding focal laser ablation.
The multi-disciplinary group assembled at UCLA (urology, radiology, pathology, biomedical engineering) has served as a model for study of image-guided diagnosis and treatment. The work which led to FDA-approval of HIFU (and publication of the data) was spearheaded by Dr. Marks at UCLA. A UCLA-backed startup, co-founded by Dr. Marks and funded in part by NCI, will soon place into trials a proprietary device for office-based focal laser ablation of prostate cancer.